Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Teva
Israel - Petach Tikva
CABERGOLINE (cabergoline) by Teva is clinical pharmacology mechanism of action: the secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Approved for hyperprolactinemic disorders, either idiopathic, due to pituitary adenomas. First approved in 2013.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Mechanism of Action: The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for…
Worked on CABERGOLINE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo